Duloxetine recalls: lots, NDC and companies
24 FDA recall records mention Duloxetine since December 11, 2024. Each covers specific lots from one company. Check yours below.
Check your Duloxetine bottle
Hazard and remedy text is quoted from the agency, unedited. The tag names the kind of risk with a word from that text. Every notice links to its official page.
Direct Rx: DULOXETINE D/R
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules and 1 more
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
FDAMedicines
Asclemed USA Inc.: Duloxetine DR Capsules
Hazard (FDA): CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules USP
Hazard (FDA): CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
FDAMedicines
Ajanta Pharma Ltd.: Duloxetine Delayed-Release Capsules and 2 more
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules and 1 more
Hazard (FDA): CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit
FDAMedicines
Direct Rx: Duloxetine D/R and 1 more
Hazard (FDA): CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
FDAMedicines
Breckenridge Pharmaceutical, Inc: Duloxetine Delayed-Release Capsules USP and 1 more
Hazard (FDA): CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.
FDAMedicines
Rising Pharma Holding, Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules and 2 more
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
FDAMedicines
The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories: Duloxetine Delayed-Release Capsules USP
Hazard (FDA): CGMP Deviations: presence of Nitrosamine Drug Substances Related Impurity (NDSRI), N-Nitroso-Duloxetine above the FDA recommended acceptable intake limit
FDAMedicines
Rising Pharma Holding, Inc.: Duloxetine Delayed-Release Capsules USP 30 mg and 2 more
Hazard (FDA): CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
FDAMedicines
Amerisource Health Services LLC: Duloxetine Delayed-Release Capsules USP and 3 more
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
FDAMedicines
PD-Rx Pharmaceuticals, Inc.: DULoxetine DR USP
Hazard (FDA): CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit
FDAMedicines
RemedyRepack Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit.
FDAMedicines
Breckenridge Pharmaceutical, Inc: Duloxetine Delayed-Release Capsules and 1 more
Hazard (FDA): CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
FDAMedicines
Amerisource Health Services LLC: Duloxetine Delayed-Release Capsules and 2 more
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
FDAMedicines
Rising Pharma Holding, Inc.: Duloxetine Delayed-Release Capsules USP and 2 more
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
FDAMedicines